



## **BX795**

Catalog No: tcsc0259

Available Sizes
Size: 5mg
Size: 10mg
Size: 25mg
Size: 50mg
Size: 100mg
Size: 200mg
Specifications
<b>CAS No:</b> 702675-74-9
Formula: C <sub>23</sub> H <sub>26</sub> IN <sub>7</sub> O <sub>2</sub> S
Pathway: PI3K/Akt/mTOR
Target: PDK-1
Purity / Grade: >98%
Solubility: DMSO : 50 mg/mL (84.54 mM; Need ultrasonic)
Observed Molecular Weight: 591.47





## **Product Description**

BX795 is a potent and selective dual inhibitor of **TBK1/PDK1** with **IC**<sub>50</sub>s of 2 nM/6 nM, respectively, and has > 50 fold selectivity over PKA, PKC, c-Kit, GSK3 $\beta$  etc.

IC50 & Target: IC50: 2 nM (TBK1), 6 nM (PDK1)

In Vitro: BX795 effectively blocks PDK1 activity in PC-3 cells, as shown by their ability to block phosphorylation of S6K1, Akt, PKCδ, and GSK3β. BX795 potently inhibits tumor cell growth on plastic with IC $_{50}$  of 1.6, 1.4, and 1.9 μM for MDA-468, HCT-116 and MiaPaca cells, respectively. In soft agar, BX795 displays higher growth inhibition with IC $_{50}$  of 0.72, and 0.25 μM for MDA-468, and PC-3 cells, respectively<sup>[1]</sup>. In addition, BX795, as an inhibitor of the TBK1/IKKε, blocks TBK1- and IKKε-mediated activation of IRF3 and production of IFN-β<sup>[2]</sup>. In platelet physiological responses, BX795 produces inhibitory effect on 2-MeSADP-induced or collageninduced aggregation, ATP secretion and thromboxane generation<sup>[3]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!